Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Assets Average (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Assets Average for 7 consecutive years, with $967.1 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 22.09% to $967.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $967.1 million through Dec 2025, up 22.09% year-over-year, with the annual reading at $927.7 million for FY2025, 26.58% up from the prior year.
  • Assets Average hit $967.1 million in Q4 2025 for BridgeBio Pharma, down from $1.0 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.1 billion in Q2 2021 to a low of $564.7 million in Q2 2023.
  • Historically, Assets Average has averaged $816.7 million across 5 years, with a median of $829.8 million in 2022.
  • Biggest five-year swings in Assets Average: tumbled 32.59% in 2023 and later surged 45.55% in 2024.
  • Year by year, Assets Average stood at $897.2 million in 2021, then dropped by 24.66% to $675.9 million in 2022, then decreased by 11.13% to $600.7 million in 2023, then skyrocketed by 31.87% to $792.2 million in 2024, then increased by 22.09% to $967.1 million in 2025.
  • Business Quant data shows Assets Average for BBIO at $967.1 million in Q4 2025, $1.0 billion in Q3 2025, and $980.9 million in Q2 2025.